As Congress considers a bill that would prevent brand-name drug makers from thwarting generic competition, Maine lawmakers are refusing to wait. The legislature recently passed a bill of its own and is now hoping the governor will sign the legislation into law.

The bill attempts to address an issue that has frustrated generic drug makers for years — tactics by brand-name companies that make it difficult, if not impossible for generic companies to obtain needed samples for developing equivalent versions.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • If memory serves, the first REMS was the FDA’s method of allowing Celgene to get a thalidomide project back on the market. And now this ‘burdensome obligation’ against innovation has become a cherished barricade ‘against innovation’ or ‘copycats’ – not just for Celgene but they are/were first in this matter as I remember.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy